Windtree Therapeutics Revenue 2006-2021 | WINT

Windtree Therapeutics revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Windtree Therapeutics Annual Revenue
(Millions of US $)
2020 $
2019 $0
2018 $2
2017 $1
2016 $2
2015 $1
2014 $3
2013 $0
2012 $0
2011 $1
2010 $
2009 $
2008 $5
2007 $
2006 $
2005 $0
Windtree Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31 $0
2019-09-30
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $1
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $1
2017-03-31 $0
2016-12-31 $1
2016-09-30 $1
2016-06-30 $0
2016-03-31 $0
2015-12-31 $1
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $0
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30 $0
2011-03-31 $0
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
2008-12-31 $0
2008-09-30 $0
2008-06-30 $3
2008-03-31 $2
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-12-31
2006-09-30
2006-06-30
2006-03-31
2005-12-31 $0
2005-09-30 $0
2005-06-30 $0
2005-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.050B $0.000B
Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree Therapeutics, Inc., formerly known as Discovery Laboratories Inc., is based in Warrington, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29